PALO ALTO VETERANS INSTITUTE FOR RESEARCH

Financials

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended September 30, 2025, highest compensation first.

Address and contacts

Address (IRS master file)

3801 MIRANDA AVE, PALO ALTO, CA 94304-1207

Principal officer (990 for 2024)

ELAINE STAATS MPH, 3801 MIRANDA AVENUE, PALO ALTO, CA 943040038

Signed the 990

ELAINE STAATS, CEO

Phone

(650) 239-2800

Website

WWW.PAVIR.ORG

Return prepared by

BAKER TILLY ADVISORY GROUP LP

California records

California keeps its own records of charities and corporations. Search them by EIN 77-0207331 or by the name PALO ALTO VETERANS INSTITUTE FOR RESEARCH.

Attorney General, Registry of Charities and Fundraisers

Registration status and filed reports (CT-TR-1, RRF-1)

Secretary of State, bizfile Online

Corporation status, entity number, agent for service

Franchise Tax Board

Entity status letter (state tax exemption, good standing)

Mission

PAVIR'S MISSION IS ADVANCING VETERANS AND PUBLIC HEALTH THROUGH INNOVATIVE RESEARCH. PAVIR WORKS WITH MORE THAN 100 PRINCIPAL INVESTIGATORS AND 200 RESEARCH STAFF TO SUPPORT BASIC SCIENCE, CLINICAL AND HEALTH SERVICES RESEARCH TO REALIZE ITS MISSION. PAVIR'S DIVERSE STUDIES SPAN THE ENTIRE SPECTRUM OF HEALTH RESEARCH FROM THE INVESTIGATION OF DISEASES IN THE LABORATORY THROUGH TESTING NEW DRUG TREATMENTS AND DEVELOPING IMPROVED MODELS OF HEALTH CARE DELIVERY TO LOOKING AT OUTCOMES BOTH INDIVIDUALLY AND ON A LARGE SCALE. PAVIR'S RESEARCH ADDRESSES HEALTH CHALLENGES THAT HAVE BEEN FACED ESPECIALLY BY VETERANS, INCLUDING POST-TRAUMATIC STRESS DISORDER, TRAUMATIC BRAIN INJURY, GERIATRIC MEDICINE, REHABILITATION, SLEEP AND OTHER VETERANS AND PUBLIC HEALTH ISSUES. PAVIR'S INVESTIGATORS HAVE APPOINTMENTS AT THE VA PALO ALTO HEALTH CARE SYSTEM AND MOST ALSO HOLD APPOINTMENTS AT THE STANFORD UNIVERSITY SCHOOL OF MEDICINE.

Program accomplishments

• CLINICAL TRANSLATION OF ALLOGENEIC REGENERATIVE CELL THERAPY FOR WHITE MATTER STROKE AND VASCULAR DEMENTIA. PRINCIPAL INVESTIGATOR: IRENE LORENZO LLORENTE, PH.D.STROKE IS THE LEADING CAUSE OF ADULT DISABILITY AND THE SECOND LEADING CAUSE OF DEMENTIA. WHITE MATTER STROKE (WMS) CONSTITUTES UP TO 30% OF ALL STROKE SUBTYPES AND IS A DISTINCT PROCESS FROM "LARGE ARTERY STROKE." WMS BEGINS AS SMALL INFARCTS IN DEEP PENETRATING BLOOD VESSELS IN THE BRAIN BUT PROGRESSES, ACCUMULATES, AND EXPANDS FROM PREEXISTING LESIONS INTO ADJACENT WHITE MATTER TO PRODUCE HEMIPARESIS WITH INCOMPLETE RECOVERY, GAIT ABNORMALITIES, COGNITIVE DECLINE, AND EXECUTIVE DYSFUNCTION CHARACTERISTIC OF VASCULAR DEMENTIA (VAD). UNLIKE LARGE ARTERY STROKE, WMS DOES NOT DAMAGE NEURONAL CELL BODIES BUT PRIMARILY AFFECTS AXONAL TRACTS AND GLIAL CELLS. A CELL-BASED THERAPY CAPABLE OF REPLACING LOST GLIA AND INDUCING STRUCTURAL REPAIR IN WMS/VAD HOLDS GREAT PROMISE. WE HAVE DEVELOPED A UNIQUE ALLOGENEIC HUMAN INDUCED PLURIPOTENT STEM CELL (HIPSC)-DERIVED GLIAL ENRICHED PROGENITOR (GEP) CELL THERAPY PRODUCT FOR THE TREATMENT OF WMS AND VAD. PRECLINICAL STUDIES DEMONSTRATE THAT HIPSC-GEPS TRANSPLANTED INTO THE BRAIN AFTER WMS/VAD PROMOTE MOTOR AND COGNITIVE RECOVERY THROUGH MULTIPLE MECHANISMS OF ACTION, INCLUDING AXONAL GROWTH, ASTROCYTIC MODULATION, OLIGODENDROCYTE DIFFERENTIATION, AND REMYELINATION. THIS YEAR, WE ACHIEVED A SUCCESSFUL PRE-IND MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR GEP-101 (HIPSC-GEPS) ON FEBRUARY 26, 2026. THE DISCUSSION, INFORMED BY THE FDA'S PRELIMINARY WRITTEN RESPONSES DATED FEBRUARY 23, 2026, FOCUSED ON FOUR PRIMARY AREAS: (1) SUITABILITY OF THE HIPSC CELL LINE AND DONOR ELIGIBILITY TESTING, (2) ADEQUACY OF THE PROPOSED CLINICAL DELIVERY DEVICE AND ADDITIONAL NONCLINICAL EVALUATION NEEDS, (3) REQUIREMENTS FOR DEVICE COMPATIBILITY TESTING TO ENSURE PRODUCT QUALITY AND DOSE ACCURACY, AND (4) QUALIFICATION OF CERTAIN MANUFACTURING RAW MATERIALS, INCLUDING THE VEEV RNA REPLICON USED DURING CELL REPROGRAMMING. OVERALL, THE FDA AGREED WITH ALL POSITIONS PRESENTED, CLARIFYING EXPECTATIONS FOR MANUFACTURING CONTROLS, DEVICE USE, AND SUPPORTING NONCLINICAL DATA PRIOR TO IND SUBMISSION.FOLLOWING THE PRE-IND MEETING, WE HAVE SUBMITTED A NEW GRANT PROPOSAL TO SECURE THE NEXT ROUND OF FUNDING AND CONTINUE ADVANCING TOWARD IND APPROVAL AND FUTURE CLINICAL TRANSLATION.
  Expenses $1,310,697
• NOVEL LYMPHOCYTE CHEMOATTRACTANT RECEPTOR AND LIGAND. PRINCIPAL INVESTIGATOR: EUGENE BUTCHER, M.D.WE HAVE IDENTIFIED A NOVEL LYMPHOCYTE CHEMOATTRACTANT RECEPTOR AND ITS CHEMOATTRACTANT LIGAND, SELECTIVELY EXPRESSED IN LUNG, AIRWAYS, UPPER GI TRACT, GENITOURINARY MUCOSAE AND MUCOSA-ASSOCIATED GLANDS INCLUDING THE PANCREAS AND SALIVARY GLANDS. AIM 1: WE WILL MECHANISTICALLY PROBE THE RECEPTOR-LIGAND INTERACTIONS FOCUSING ON THE SPECIFICITY AND SIGNALING PATHWAYS ACTIVATED BY THE NOVEL RECEPTOR AND ITS ROLE AS A LYMPHOCYTE VS MYELOID CELL CHEMOTACTIC RECEPTOR. STRUCTURE-FUNCTION STUDIES WILL IDENTIFY LIGAND DOMAINS FOR RECEPTOR BINDING AND ACTIVATION. AIM 2: WILL DEFINE THE REGULATION OF THE RECEPTOR IN THE MOUSE, AND ITS ROLE IN LYMPHOCYTE POPULATION OF AND HOMING TO NON-LYMPHOID TISSUES DURING HOMEOSTASIS AND IN THE SETTING OF CHRONIC MULTI-ORGAN AUTOIMMUNE INFLAMMATION. THE ROLES OF THE PATHWAY IN IMMUNE CELL DEVELOPMENT WILL BE PROBED IN MIXED BONE MARROW CHIMERAS IN WHICH RECEPTOR-DEFICIENT VS WILD TYPE STEM CELLS COMPETE FOR RECONSTITUTION OF IMMUNE COMPARTMENTS IN LYMPHOID AND NON-LYMPHOID TISSUES. AIM 3: WILL ELUCIDATE THE TISSUE- AND CELL SUBSET-SPECIFIC EXPRESSION OF THE RECEPTOR AND LIGAND IN HUMANS.WHILE MUCH OF AIM 1 HAS BEEN COMPLETED AND PRESENTED IN OUR NATURE PUBLICATION, THIS AIM AS WELL AS THE GRANT AS A WHOLE HAS AS ITS OVERARCHING GOAL TO IDENTIFY AND CHARACTERIZE THE GPCR INTERACTIONS AND FUNCTIONS OF CXCL17. OUR ALPHA FOLD MODELING SUPPORTED OUR INITIAL CHARACTERIZATION OF CXCL17-GPR25 INTERACTION. USING THIS AS A JUMPING OFF POINT, WE ARE ASKING WHETHER IN SILICO MODELING IN SCREENING MODE CAN IDENTIFY THE FUNCTIONAL GPCR LIGANDS OF CXCL17 (AND THUS POTENTIALLY OF OTHER ORPHAN CHEMOKINES). IN HIGH THROUGHPUT SCREENING MODE, WE GENERATED AF2 MODELS OF CXCL17 INTERACTIONS WITH ALL CLASS A GPCRS AND FIND THAT THE HIGHEST SCORING MODELS INCLUDE GPR25 BUT ALSO TWO OTHER RECEPTORS: BDKRB1, THE INFLAMMATION ASSOCIATED BRADYKININ RECEPTOR, AND NTSR2, THE NEUROTENSIN RECEPTOR. OTHER RECEPTORS SHOWED NO OR UNFAVORABLE INTERACTIONS (DEFINED BY AF2 METRICS INCLUDING IPTM ON LIGAND AND RECEPTOR RESIDUES INTERACTING IN THE LIGAND BIND POCKET OF THE GPCR). THESE IN SILICO FINDINGS SUGGEST THE POSSIBILITY OF ADDITIONAL RECEPTORS FOR CXCL17 THAT COULD IMPACT VASCULAR AND NEUROBIOLOGY. A MAJOR FOCUS THIS YEAR IN REGARDS TO AIM 2 HAS BEEN ON EXPANDING AND INITIALLY CHARACTERIZING GPR25 DEFICIENT MICE, TO DEFINE THE ROLE OF GPR25 IN LYMPHOCYTE SUBSET REPRESENTATION AND DISTRIBUTION IN MUCOSAL TISSUES. WE HAVE ESTABLISHED THE COLONY AND HAVE EVALUATED BASAL LYMPHOCYTE SUBSETS IN THE RESTING STATE. THE RESULTS LARGELY PARALLEL THOSE IN CXCL17 DEFICIENT MICE, INDICATING THAT CXCL17 IS LIKELY THE ONLY OR THE PREDOMINANT CHEMOKINE LIGAND FOR GPR25. WE HAVE GENERATED MIXED (WT/KO) BONE MARROW CHIMERAS TO DEFINE THE EFFECT OF GPR25 DEFICIENCY BY EVALUATING KO LYMPHOCYTE REPRESENTATION IN COMPETITION WITH WT CELLS IN THE SAME HOST.FOR AIM 3, WE CONTINUE TO EVALUATE GPR25 EXPRESSION IN HUMAN AND MOUSE DISEASE MODELS (SCRNA SEQ DATA TO DATE FROM PUBLIC RESOURCES). WE ARE INTERESTED IN GWAS ASSOCIATIONS OF GPR25 WITH ARTERIAL STIFFNESS: WE SEE SIGNIFICANT T CELL SUBSET EXPRESSION OF GPR25 IN DATA FROM HUMAN CORONARY ARTERY DISEASE. WE ARE ALSO INTERESTED IN UNDERSTANDING THE GWAS ASSOCIATIONS OF HUMAN BLOOD GPR25 WITH AUTOIMMUNE DISEASES ESPECIALLY IBD: THROUGH COLLABORATION WITH DR. MONTGOMERY, COLOCALIZATION ANALYSIS INDICATE THAT GPR25 HAS THE HIGHEST PP4 AMONG GENES IN THE REGION FOR IBD, CROHN'S DISEASE, AND ULCERATIVE COLITIS, PRIORITIZING GPR25 AS THE LIKELY CAUSAL GENE AT THIS LOCUS. WE HAVE PERFORMED RNA SCOPE ON INTESTINAL SAMPLES FROM IBD PATIENTS (WITH OUR COLLABORATOR AND CO-INVESTIGATOR SERENA TAN) REVEALING STRONG CXCL17 EXPRESSION WITHIN SITES OF PYLORIC METAPLASIA CONSISTENT WITH SINGLE-CELL RNA-SEQ DATA AND SUPPORTING RECRUITMENT OF GPR25 IMMUNE CELLS TO INFLAMED MUCOSA. RECRUITMENT OF GPR25+ TREGS COULD EXPLAIN THE ROLE OF HIGHER PBMC GPR25 IN REDUCING IBD.
  Expenses $1,238,218
• ALL OF US RESEARCH PROGRAM. PRINCIPAL INVESTIGATORS: PHILIP TSAO, PH.D. THE ALL OF US RESEARCH PROGRAM (ALL OF US) IS A LARGE COLLABORATIVE INITIATIVE SPONSORED BY THE NATIONAL INSTITUTES OF HEALTH (NIH). ALL OF US INCLUDES A CONSORTIUM OF AWARDEES FROM MULTIPLE INSTITUTIONS, INCLUDING THE DEPARTMENT OF VETERANS AFFAIRS. ALL OF US IS WORKING TO IMPROVE HEALTHCARE THROUGH RESEARCH BY BUILDING A DIVERSE DATABASE OF PARTICIPANT SELF-REPORT INFORMATION, BIOSPECIMENS, AND ELECTRONIC HEALTH RECORDS THAT CAN INFORM FUTURE RESEARCH ON A VARIETY OF HEALTH CONDITIONS. VA PARTICIPATION IN ALL OF US IS OVERSEEN BY TWO CO-PIS, LOCATED AT THE VA PALO ALTO HEALTHCARE SYSTEM AND THE VA BOSTON HEALTHCARE SYSTEM. THESE TWO INSTITUTIONS SERVE AS THE COORDINATING CENTERS FOR VA RESPONSIBLE FOR CENTRALIZED RECRUITMENT, ENGAGEMENT CAMPAIGNS, AND COMPLIANCE WITH PROGRAM REQUIREMENTS.
  Expenses $1,062,166
• PAVIR IS PRIVILEGED TO WORK WITH A LARGE COMMUNITY OF UNIQUELY TALENTED MEDICAL RESEARCHERS ACROSS A BROAD SPECTRUM OF RESEARCH AREAS AS WE FULFILL OUR MISSION OF ADVANCING VETERANS AND PUBLIC HEALTH THROUGH INNOVATIVE RESEARCH. THE RANGE OF RESEARCH ACTIVITIES IS BROAD AND INCLUDES SPECIAL EMPHASIS ON MAJOR DISEASE CATEGORIES, ALL OF WHICH ARE PREVALENT IN THE VA'S PATIENT POPULATION. THESE INCLUDE CARDIOVASCULAR MEDICINE, MENTAL HEALTH, CHRONIC INFLAMMATORY DISEASE, STEM CELL/REGENERATIVE MEDICINE, PAIN, SLEEP DISORDERS, AND MANY OTHERS. IN ADDITION TO DISEASE SPECIFIC RESEARCH, PAVIR IS ENGAGED IN SUPPORTING RESEARCH AIMED AT ENHANCING HEALTH CARE. PAVIR'S RESEARCH PORTFOLIO INCLUDES COMPARATIVE STUDIES IN WHICH RESEARCH TEAMS ARE LEARNING WHICH TREATMENTS ARE SUPERIOR TO OTHERS, HOW TO AUGMENT OR IMPROVE STANDARD OF CARE, AS WELL AS HOW TO ENHANCE THE OPERATION OF HEALTH CARE. FURTHERMORE, PAVIR IS SUPPORTING EDUCATIONAL ACTIVITIES, ESPECIALLY IN AREAS OF ADVANCING CLINICAL CARE FOR VETERANS AND FOSTERING THE PROFESSIONAL DEVELOPMENT OF OUR EXPERT STAFF.
  Expenses $24,180,777 · revenue $10,144,436

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in September, so each return is due on the 15th day of the 5th month after that.

IRS record

EIN

77-0207331

Tax-exempt status

501(c)(3): Charitable, religious, educational or scientific organization

Foundation status

Hospital or medical research organization

Donations deductible (Pub 78)

Public charity, 50% deduction limit

Exempt since

1996

Accounting year ends

September

Files

Form 990 or 990-EZ

Category (NTEE)

Medical research (H00E)

Assets (IRS master file)

$19,146,651

Income (IRS master file)

$35,854,131

Filing history

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 77-0207331).

Questions about PALO ALTO VETERANS INSTITUTE FOR RESEARCH

What is the EIN of PALO ALTO VETERANS INSTITUTE FOR RESEARCH?

The employer identification number (EIN) of PALO ALTO VETERANS INSTITUTE FOR RESEARCH is 77-0207331.

Is PALO ALTO VETERANS INSTITUTE FOR RESEARCH tax-exempt?

Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1996.

Are donations to PALO ALTO VETERANS INSTITUTE FOR RESEARCH tax-deductible?

Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).

Which annual return does PALO ALTO VETERANS INSTITUTE FOR RESEARCH file?

Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.

When is the next return of PALO ALTO VETERANS INSTITUTE FOR RESEARCH due?

The return for tax year 2025 (the year ending September 30, 2026) is due February 16, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.

When did PALO ALTO VETERANS INSTITUTE FOR RESEARCH last file with the IRS?

The latest return in the IRS public files is the 990 for the year ended September 2025.

Who is the principal officer of PALO ALTO VETERANS INSTITUTE FOR RESEARCH?

The 990 for the year ended September 30, 2025 names ELAINE STAATS MPH.

Who are the officers and directors of PALO ALTO VETERANS INSTITUTE FOR RESEARCH?

The 990 for the year ended September 30, 2025 lists 25 people; 11 received compensation from the organization, the highest $282,965 (ELAINE STAATS, CHIEF EXECUTIVE OFFICER).

How much revenue does PALO ALTO VETERANS INSTITUTE FOR RESEARCH have?

On its 990 for the year ended September 30, 2025 it reported revenue of $35,854,131, expenses of $33,029,388 and total assets of $19,146,651 at year end.

Other nonprofits in PALO ALTO

• ARC RESEARCH INSTITUTE
  EIN 87-1920284 · last filed 990 for 2024
• CYSTIC FIBROSIS RESEARCH INSTITUTE
  EIN 51-0169988 · last filed 990 for 2024
• A FOUNDATION BUILDING STRENGTH INC
  EIN 26-1761329 · last filed 990 for 2024
• HARVEY BASSETT CLARKE FOUNDATION
  EIN 94-6104609 · last filed 990-EZ for 2025
• IRON HORSE FOUNDATION
  EIN 30-0841411 · last filed 990-N for 2025
• SCITON MEDICAL FOUNDATION
  EIN 92-2451235 · last filed 990 for 2025
• JEN-HSUN & LORI HUANG FOUNDATION
  EIN 26-1551239 · last filed 990-PF for 2024
• LUCILE SALTER PACKARD CHILDRENS HOSPITAL AT STANFORD
  EIN 77-0003859 · last filed 990 for 2025

All nonprofits in PALO ALTO · California · Medical research